Health Canada approved AstraZeneca’s rare‑disease drug Koselugo (selumetinib) on March 9, 2026 for adult patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas.
Koselugo is an oral, selective MEK inhibitor that blocks the MEK1/2 enzymes driving tumor growth. The approval is based on the Phase III KOMET trial, which showed a 20 % objective response rate in tumor size reduction versus 5 % for placebo. The drug had already received U.S. approval in November 2025 for adult NF1 and has been approved in other regions for both adults and children.
The Canadian approval expands AstraZeneca’s rare‑disease portfolio and adds a new revenue stream in a market with limited treatment options. It aligns with the company’s strategy to strengthen its rare‑disease presence following the 2021 acquisition of Alexion Pharmaceuticals, positioning AstraZeneca as a leading provider of therapies for rare genetic disorders.
For patients, the approval provides a new oral treatment option that can reduce tumor size and alleviate symptoms associated with plexiform neurofibromas, improving quality of life for a condition that has historically had few therapeutic choices.
The approval underscores AstraZeneca’s commitment to delivering innovative therapies for rare diseases and is expected to contribute positively to the company’s future earnings profile as the drug enters the Canadian market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.